SYS-6040

N/A

Report date: 2025/10/20 14:43:30

Base Information

Drug NameSYS-6040
Drug Alias NameSYS6040SYS-6040
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2Tubulin inhibitorsDelta-like protein 3 modulators
TargetsReceptor protein-tyrosine kinase erbB-2TubulinDelta-like protein 3
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaNeuroendocrine Tumors +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJushi Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdCSPC Megalith Biopharmaceutical Co LtdJushi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaNeuroendocrine Tumors +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A